Literature DB >> 26576785

The close linkage between the elasticity modulus measured by real-time mapping shear wave elastography and the presence of hepatocellular carcinoma in patients with a sustained virological response to interferon for chronic hepatitis C.

Yasuharu Imai1, Jun-Ichi Taira2, Mayumi Okada2, Mayumi Ando2, Takatomo Sano2, Yuhki Miyata2, Katsutoshi Sugimoto2, Ikuo Nakamura2, Fuminori Moriyasu2.   

Abstract

PURPOSE: Some patients develop hepatocellular carcinoma (HCC) after sustained virological response (SVR) to interferon therapy for chronic hepatitis C (CH-C). The aim of this study was to examine the linkage between liver elasticity and the presence/absence of HCC in patients after SVR.
METHODS: We enrolled 42 patients who underwent real-time mapping shear wave elastography (SWE) after SVR to interferon therapy for CH-C. Of the 42 patients, six had HCC and 36 did not. We retrospectively compared the elasticity modulus and other clinical parameters between patients with and without HCC.
RESULTS: Elasticity modulus measured by SWE, age, and serum albumin was significantly different between patients with and without HCC. Age, Fibrosis-4 index, serum gamma-globulin, total protein, and albumin levels were significantly correlated with the elasticity modulus. Areas under receiver operating characteristic curves of elasticity modulus, gamma-globulin, and age for the presence of HCC were 0.963, 0.888, and 0.778, respectively. In patients with an elasticity modulus ≥6.5 kPa, both sensitivity and specificity for the presence of HCC were 83.3 %.
CONCLUSION: The study demonstrated the close linkage between the elasticity modulus measured by SWE and the presence of HCC in patients after SVR.

Entities:  

Keywords:  Hepatitis C virus infection; Hepatocellular carcinoma; Shear wave elastography; Sustained virological response

Mesh:

Substances:

Year:  2014        PMID: 26576785     DOI: 10.1007/s10396-014-0604-2

Source DB:  PubMed          Journal:  J Med Ultrason (2001)        ISSN: 1346-4523            Impact factor:   1.314


  28 in total

1.  Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.

Authors:  A Kasahara; N Hayashi; K Mochizuki; M Takayanagi; K Yoshioka; S Kakumu; A Iijima; A Urushihara; K Kiyosawa; M Okuda; K Hino; K Okita
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

2.  Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

Authors:  K Ikeda; S Saitoh; Y Arase; K Chayama; Y Suzuki; M Kobayashi; A Tsubota; I Nakamura; N Murashima; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

3.  Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan.

Authors:  Jing-Houng Wang; Chi-Sin Changchien; Chao-Hung Hung; Wei-Chih Tung; Kwong-Ming Kee; Chien-Hung Chen; Tsung-Hui Hu; Chuan-Mo Lee; Sheng-Nan Lu
Journal:  J Gastroenterol Hepatol       Date:  2010-05       Impact factor: 4.029

4.  Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study.

Authors:  J Foucher; E Chanteloup; J Vergniol; L Castéra; B Le Bail; X Adhoute; J Bertet; P Couzigou; V de Lédinghen
Journal:  Gut       Date:  2005-07-14       Impact factor: 23.059

5.  Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.

Authors:  S Kobayashi; T Takeda; M Enomoto; A Tamori; N Kawada; D Habu; H Sakaguchi; T Kuroda; K Kioka; S R Kim; T Kanno; T Ueda; M Hirano; S Fujimoto; H Jomura; S Nishiguchi; S Seki
Journal:  Liver Int       Date:  2007-03       Impact factor: 5.828

6.  The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.

Authors:  Roberta D'Ambrosio; Alessio Aghemo; Mirella Fraquelli; Maria Grazia Rumi; Maria Francesca Donato; Valerie Paradis; Pierre Bedossa; Massimo Colombo
Journal:  J Hepatol       Date:  2013-03-23       Impact factor: 25.083

7.  Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients.

Authors:  Hsin-Ming Wang; Chao-Hung Hung; Sheng-Nan Lu; Chien-Hung Chen; Chuan-Mo Lee; Tsung-Hui Hu; Jing-Houng Wang
Journal:  Liver Int       Date:  2013-02-14       Impact factor: 5.828

8.  Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C.

Authors:  K Kaserer; R Fiedler; P Steindl; C H Müller; F Wrba; P Ferenci
Journal:  Histopathology       Date:  1998-05       Impact factor: 5.087

9.  Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

Authors:  S Nishiguchi; T Kuroki; S Nakatani; H Morimoto; T Takeda; S Nakajima; S Shiomi; S Seki; K Kobayashi; S Otani
Journal:  Lancet       Date:  1995-10-21       Impact factor: 79.321

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  1 in total

1.  The state of ultrasound technology in the diagnosis and treatment of liver diseases now and in the future.

Authors:  Yasuharu Imai
Journal:  J Med Ultrason (2001)       Date:  2018-04       Impact factor: 1.314

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.